Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedUpdated revision tag from v3.5.3 to v3.5.4, indicating a newer version of the page metadata.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision tag updated from v3.5.2 to v3.5.3, indicating a small update to the page's revision history and release notes.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check64 days agoChange DetectedLayout and formatting updates to the study record page were observed. Core study content like eligibility criteria, outcomes, and enrollment status remains unchanged.SummaryDifference0.1%

- Check71 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check78 days agoChange DetectedRevision tag on the page updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.